Alkem Laboratories shareholders approved all six resolutions proposed at the company's 52nd Annual General Meeting (AGM) held on August 27, 2026. The meeting was conducted through video conferencing and other audio-visual means, with Executive Chairman Basudeo N. Singh presiding over the proceedings.

The company provided remote e-voting facilities from August 24 to August 26, 2026, followed by e-voting during the AGM for attending members. A total of 77 members attended the virtual meeting, representing both promoter and public shareholding categories.

Key Resolutions Approved

Shareholders approved the adoption of audited standalone and consolidated financial statements for FY26. The meeting also confirmed the payment of interim dividend and declared a final dividend on equity shares for the financial year ended March 31, 2026.

Board appointments received shareholder approval:

• Sandeep Singh, Managing Director, was re-appointed after retiring by rotation
• Sarvesh Singh was re-appointed following retirement by rotation
• Madhurima Singh was re-appointed as Executive Director for five years, from December 20, 2026, to December 19, 2031

The company also ratified remuneration for Suresh D. Shenoy as Cost Auditor for FY26.

Voting Results

What the Numbers Show

Promoter group participation remained consistent across most resolutions, with approximately 99.09% of promoter-held shares voting in favour of financial statement adoption and dividend declaration. However, promoter voting participation dropped to 77.38% for Madhurima Singh's re-appointment, where promoters are classified as interested parties under SEBI LODR regulations.

Public institutional investors showed varying approval rates for director appointments. Sandeep Singh's re-appointment received 81.89% support from public institutions, while Sarvesh Singh secured 94.95% backing from the same category. These divergences suggest differentiated shareholder perspectives on individual director tenures despite overall resolution passage.

HDFC Mutual Fund schemes increased their aggregate holding in Alkem Laboratories to 5.017% on August 24, 2026. The acquisition pushed the fund’s stake above the 5% threshold mandated for disclosure under SEBI regulations.

The purchase of 25,019 shares was executed through the open market. This transaction raised the fund’s total shareholding from 59,73,409 shares (4.996%) to 59,98,428 shares.

Regulatory Disclosure

The disclosure was filed in compliance with Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. HDFC Asset Management Company Limited, the investment manager for HDFC Mutual Fund, submitted the details to Alkem Laboratories and the stock exchanges where the company is listed.

The filing confirms that none of the acquired shares carry encumbrances such as pledges or liens. There were no changes in voting rights otherwise than by shares, nor any acquisition of warrants or convertible securities.

Portfolio Composition

The stake is held across multiple HDFC Mutual Fund schemes acting as persons acting in concert (PAC). Key funds involved in the holding include:

• HDFC BSE 500 ETF
• HDFC BSE 500 Index Fund
• HDFC Arbitrage Fund
• HDFC Value Fund
• HDFC Balanced Advantage Fund
• HDFC Large and Mid Cap Fund
• HDFC Pharma and Healthcare Fund
• HDFC Mid Cap Fund

Capital Structure Context

Alkem Laboratories has a paid-up equity share capital of ₹23,91,30,000, comprising 11,95,65,000 equity shares of ₹2 each. The total diluted share/voting capital remains unaffected as no convertible instruments were involved in this transaction.